Cryo-Cell International, Inc. (CCEL) P/E Ratio History
Historical price-to-earnings valuation from 2001 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Cryo-Cell International, Inc. (CCEL) trades at a price-to-earnings ratio of 67.4x, with a stock price of $3.37 and trailing twelve-month earnings per share of $0.05.
The current P/E is roughly in line with its 5-year average of 71.6x. Over the past five years, CCEL's P/E has ranged from a low of 12.0x to a high of 790.0x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, CCEL trades at a 185% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, CCEL commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CCEL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Healthcare staffing and facility services peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SOLVSolventum Corporation | $13B | 8.4 | - | +222% |
HCSGHealthcare Services Group, Inc. | $2B | 26.9 | - | +53% |
CCELCryo-Cell International, Inc. | $27M | 67.4 | - | +104% |
AMSAmerican Shared Hospital Services | $14M | 6.4Lowest | 0.97Best | +246%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Fri Feb 28 2025 00:00:00 GM | $7.90 | $0.01 | 790.0x | +811% |
| FY2024 Q4 | Sat Nov 30 2024 00:00:00 GM | $8.67 | $0.05 | 182.9x | +111% |
| FY2023 Q3 | $6.00 | $0.30 | 20.0x | -77% | |
| FY2023 Q2 | Wed May 31 2023 00:00:00 GM | $4.85 | $0.28 | 17.6x | -80% |
| FY2023 Q1 | $3.82 | $0.32 | 12.0x | -86% | |
| FY2022 Q4 | Wed Nov 30 2022 00:00:00 GM | $4.37 | $0.32 | 13.5x | -84% |
| FY2022 Q3 | Wed Aug 31 2022 00:00:00 GM | $7.37 | $0.15 | 48.6x | -44% |
| FY2022 Q2 | $6.13 | $0.20 | 31.3x | -64% | |
| FY2022 Q1 | Mon Feb 28 2022 00:00:00 GM | $8.13 | $0.26 | 31.1x | -64% |
| FY2021 Q4 | $12.38 | $0.25 | 50.2x | -42% | |
| FY2021 Q3 | $11.60 | $0.48 | 24.2x | -72% | |
| FY2021 Q2 | Mon May 31 2021 00:00:00 GM | $8.65 | $0.48 | 18.0x | -79% |
Average P/E for displayed period: 86.7x
See CCEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCEL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CCEL vs AGIO
See how CCEL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CCEL stock overvalued or undervalued?
CCEL trades at 67.4x P/E, near its 5-year average of 71.6x. The 90th percentile ranking places valuation within normal historical bounds.
How does CCEL's valuation compare to peers?
Cryo-Cell International, Inc. P/E of 67.4x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is CCEL's PEG ratio?
CCEL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2001-2025.